Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315)

Puntos clave

• Institutional variability in genetic testing practices impacts patient care, revealing significant differences in approaches.
• The analysis indicates that this variability is not explained by patient or tumor characteristics, implying other factors at play.
• Observational analysis from the CRISP registry highlights the need for understanding genetic testing discrepancies across institutions.
• Calls for standardized testing protocols could enhance patient outcomes and address existing inconsistencies in practice.

Resumen